ContraFect Corp Company Profile (NASDAQ:CFRXU)

About ContraFect Corp

ContraFect Corp logoContraFect Corporation (ContraFect ) is a biotechnology company. The Company is focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. It intends to address drug-resistant infections using its therapeutic product candidates from its lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). Its product candidates are CF-301, a lysin for the treatment of Staph aureus bacteremia, and CF-404, a combination of mAbs for the treatment of life-threatening seasonal and pandemic varieties of influenza. CF-301 and CF-302 are bacteriophage lysins with potent activity against Staph aureus infections.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CFRXU
  • CUSIP:
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $N/A
  • 200 Day Moving Average: $N/A
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.74
  • P/E Growth: N/A
  • Market Cap: $N/A
Additional Links:

Analyst Ratings

Consensus Ratings for ContraFect Corp (NASDAQ:CFRXU) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for ContraFect Corp (NASDAQ:CFRXU)
Show:
DateFirmActionRatingPrice TargetDetails
10/6/2014Roth CapitalInitiated CoverageBuyView Rating Details
(Data available from 9/29/2014 forward)

Earnings

Earnings History for ContraFect Corp (NASDAQ:CFRXU)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for ContraFect Corp (NASDAQ:CFRXU)
Current Year EPS Consensus Estimate: $-3.29 EPS
Next Year EPS Consensus Estimate: $-2.00 EPS

Dividends

Dividend History for ContraFect Corp (NASDAQ:CFRXU)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ContraFect Corp (NASDAQ:CFRXU)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for ContraFect Corp (NASDAQ:CFRXU)
DateHeadline
noodls.com logoContraFect to Present at 27th Annual ROTH Conference (NASDAQ:CFRXU)
us.rd.yahoo.com - January 14 at 11:01 AM
noodls.com logoContraFect Corporation Announces Fourth Quarter and Full Year 2014 Results (NASDAQ:CFRXU)
us.rd.yahoo.com - January 14 at 11:01 AM
noodls.com logoContraFect Corporation Announces Commencement of Phase 1 Clinical Trial of CF-301 for Staph Bloodstream Infections, Including MRSA (NASDAQ:CFRXU)
us.rd.yahoo.com - January 14 at 11:01 AM
noodls.com logoContraFect Corporation Announces First Quarter 2015 Results (NASDAQ:CFRXU)
us.rd.yahoo.com - January 14 at 11:01 AM
noodls.com logoContraFect Corporation Adds Former Cubist Executive Steven C. Gilman, PhD, to Board of Directors as Executive Chairman (NASDAQ:CFRXU)
us.rd.yahoo.com - January 14 at 11:01 AM
noodls.com logoContraFect Corporation Announces First Healthy Volunteer Dosed With CF-301 (NASDAQ:CFRXU)
us.rd.yahoo.com - January 14 at 11:01 AM
noodls.com logoContraFect Corporation Announces Second Quarter 2015 Financial and Operating Results (NASDAQ:CFRXU)
us.rd.yahoo.com - January 14 at 11:01 AM

Social

ContraFect Corp (NASDAQ:CFRXU) Chart for Thursday, September, 29, 2016


Last Updated on 9/29/2016 by MarketBeat.com Staff